Zimbabwe - English - Medicines Control Authority

adcock ingram limited - clotrimazole - cream; topical - 50mg/5g

Zimbabwe - English - Medicines Control Authority

adcock ingram limited - piroxicam - capsule; oral - 10mg

Kenya - English - Pharmacy and Poisons Board

adcock ingram east africa ltd. p.o. box 101674-00101 nairobi - cetrizine hydrochloride 10mg - tablet - cetrizine hydrochloride 10mg - antihistamines for systemic use: piperazine

Kenya - English - Pharmacy and Poisons Board

adcock ingram ltd. p.o. box 101674-00101 nairobi - bromhexine hcl 4mg orciprenaline sulphate 5mg - syrup - bromhexine hcl 4mg orciprenaline sulphate 5mg - expectorants excluding combinations with cough

Kenya - English - Pharmacy and Poisons Board

adcock ingram limited 1 new road, erand gardens, midrand, 1685, - loperamide hcl 2mg - tablet - loperamide hcl 2mg - antipropulsives

Kenya - English - Pharmacy and Poisons Board

adcock ingram east africa ltd. p.o. box 101674-00101 nairobi - sodium bicarbonate 1.716gm tartaric acid 0.858gm… - powder for syrup - sodium bicarbonate 1.716gm tartaric acid 0.858gm… - antacids with sodium bicarbonate

Kenya - English - Pharmacy and Poisons Board

adcock ingram ltd. p.o. box 101674-00101 nairobi - paracetamol 500mg - tablet - paracetamol 500mg - non-opioid analgesics andantipyretics: anilides

Zimbabwe - English - Medicines Control Authority

adcock ingram limited - loperamide - tablet; oral - 2mg

Zimbabwe - English - Medicines Control Authority

adcock ingram limited - acyclovir - cream; topical - 250mg/5g

United States - English - NLM (National Library of Medicine)

united therapeutics corporation - tadalafil (unii: 742sxx0ict) (tadalafil - unii:742sxx0ict) - tadalafil 20 mg - adcirca® is indicated for the treatment of pulmonary arterial hypertension (pah) (who group 1) to improve exercise ability. studies establishing effectiveness included predominately patients with nyha functional class ii – iii symptoms and etiologies of idiopathic or heritable pah (61%) or pah associated with connective tissue diseases (23%). adcirca is contraindicated in patients who are using any form of organic nitrate, either regularly or intermittently. do not use nitrates within 48 hours of the last dose of adcirca. adcirca potentiates the hypotensive effect of nitrates. this potentiation is thought to result from the combined effects of nitrates and adcirca on the nitric oxide/cgmp pathway [see clinical pharmacology (12.2)] . coadministration of gc stimulators such as riociguat with adcirca is contraindicated. adcirca may potentiate the hypotensive effects of gc stimulators. adcirca is contraindicated in patients with a known serious hypersensitivity to tadalafil (adcirca or cialis). hypersensitivity